head of
- Applied Genomics and Cancer Therapeutics Principal Investigator 2017 -
- Contact Info
- 505-925-0843
Chien, Jeremy Associate Professor in Division of Molecular Medicine
Positions
- Associate Professor, Department of Internal Medicine 2017 -
The primary objectives of my research program in Applied Genomics and Cancer Therapeutics (AGCT) are to crack the genetic codes of ovarian cancer, to understand the genetic basis of ovarian cancer, and to translate this knowledge into clinical applications to improve the early detection and the treatment of ovarian cancer. To support these objectives, my current research focuses on three areas: Cancer Genomics, Functional Genomics, and Precision Cancer Therapeutics.
Research Areas
- Affiliation
- Publications
- Research
- Service
- Background
- Contact
- Identity
- View All
Affiliation
member of
- UNM Comprehensive Cancer Center Member 2017 -
has collaborator
- Bologa, Cristian G. Research Professor
- Oprea, Tudor I. Professor
- Sklar, Larry Director – Translational Technology & Resources
Publications
selected publications
-
academic article
- Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.. Clinical cancer research : an official journal of the American Association for Cancer Research. 23:3794-3801. 2017
- VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.. Molecular oncology. 10:1559-1574. 2016
- Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.. The Journal of biological chemistry. 291:18897-18914. 2016
- Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.. Molecular oncology. 10:1099-1117. 2016
- The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.. Oncotarget. 7:27185-27198. 2016
- A targeted genetic association study of epithelial ovarian cancer susceptibility.. Oncotarget. 7:7381-7389. 2016
- Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.. BMC cancer. 15:-. 2015
- Neonatal Progesterone Programs Adult Uterine Responses to Progesterone and Susceptibility to Uterine Dysfunction.. Endocrinology. 156:3791-3803. 2015
- Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.. Breast cancer research : BCR. 17:-. 2015
- Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics.. Oncotarget. 6:25943-25961. 2015
- TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.. Nucleic acids research. 43:6945-6958. 2015
- Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples.. Scientific reports. 5:-. 2015
- PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.. European journal of cancer (Oxford, England : 1990). 51:879-892. 2015
- Challenges and opportunities for next-generation sequencing in companion diagnostics.. Expert review of molecular diagnostics. 15:193-209. 2015
- Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.. Oncotarget. 5:11365-11380. 2014
- Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.. Cancer research. 74:3084-3091. 2014
- Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.. Scientific reports. 4:-. 2014
- Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer.. BMC medical genomics. 7:-. 2014
- Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer.. Cancer & metabolism. 2:-. 2014
- APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.. Cancer research. 73:7222-7231. 2013
- Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment.. Frontiers in oncology. 3:-. 2013
- Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.. Human molecular genetics. 22:3038-3047. 2013
- Metformin intake is associated with better survival in ovarian cancer: a case-control study.. Cancer. 119:555-562. 2013
- Assessment of resistance to anoikis in ovarian cancer.. Methods in molecular biology (Clifton, N.J.). 1049:347-354. 2013
- Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.. PLoS computational biology. 9:-. 2013
- Role of heparan sulfatases in ovarian and breast cancer.. American journal of cancer research. 3:34-45. 2013
- HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.. International journal of cancer. Journal international du cancer. 130:1029-1035. 2012
- Highly parallel genome-wide expression analysis of single mammalian cells.. PloS one. 7:-. 2012
- Assessment of hepatocyte growth factor in ovarian cancer mortality.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20:1638-1648. 2011
- FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq.. Bioinformatics (Oxford, England). 27:1708-1710. 2011
- HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.. Cancer research. 71:2152-2161. 2011
- Comparison of gene expression patterns between avian and human ovarian cancers.. Gynecologic oncology. 120:256-264. 2011
- Expression and functional significance of HtrA1 loss in endometrial cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17:427-436. 2011
- Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 24:277-287. 2011
- Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.. Cancer research. 70:3109-3118. 2010
- High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.. The Journal of biological chemistry. 285:12011-12027. 2010
- TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway.. Oncogene. 29:1362-1373. 2010
- Serine protease HtrA1 associates with microtubules and inhibits cell migration.. Molecular and cellular biology. 29:4177-4187. 2009
- Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.. Gynecologic oncology. 114:3-11. 2009
- HtrA serine proteases as potential therapeutic targets in cancer.. Current cancer drug targets. 9:451-468. 2009
- Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening.. Journal of cellular biochemistry. 107:253-263. 2009
- A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation.. Oncogene. 27:7223-7234. 2008
- Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion.. American journal of obstetrics and gynecology. 199:557.e1-557.10. 2008
- Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.. The Journal of clinical investigation. 118:2908-2916. 2008
- The serine protease HtrA1 is a novel prognostic factor for human mesothelioma.. Pharmacogenomics. 9:1069-1077. 2008
- Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.. Journal of cellular biochemistry. 102:1117-1129. 2007
- Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.. Oncogene. 26:4969-4978. 2007
- Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.. The Journal of biological chemistry. 282:14413-14420. 2007
- A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.. Science (New York, N.Y.). 314:992-993. 2006
- Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 12:6133-6143. 2006
- DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein.. Biochemical and biophysical research communications. 347:22-30. 2006
- Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.. The Journal of clinical investigation. 116:1994-2004. 2006
- HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.. Cancer research. 66:6025-6032. 2006
- Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance.. Cancer research. 65:7091-7095. 2005
- Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.. Oncogene. 24:5089-5100. 2005
- A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer.. Oncogene. 23:1636-1644. 2004
- HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma.. Oncogene. 23:1439-1447. 2004
- hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling.. Gastroenterology. 126:231-248. 2004
- Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.. The Journal of biological chemistry. 278:23107-23117. 2003
- Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.. Cancer research. 62:262-270. 2002
- Calcitonin is expressed in gonadotropes of the anterior pituitary gland: its possible role in paracrine regulation of lactotrope function.. The Journal of endocrinology. 171:217-228. 2001
- Calcitonin is a prostate epithelium-derived growth stimulatory peptide.. Molecular and cellular endocrinology. 181:69-79. 2001
- Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells.. International journal of cancer. 91:46-54. 2001
- Calcitonin inhibits anterior pituitary cell proliferation in the adult female rats.. Endocrinology. 140:4281-4291. 1999
- Constitutive activation of stimulatory guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells.. Oncogene. 18:3376-3382. 1999
-
proceedings
- Summary of the 2015 American Association for Cancer Research (AACR) Annual Meeting.. Gynecologic oncology. 7-10. 2015
- Molecular determinants of chemotherapy resistance in ovarian cancer.. Pharmacogenomics. 1763-1767. 2015
Research
research overview
-
My research program in Applied Genomics and Cancer Therapeutics focuses on three areas: Cancer Genomics, Functional Genomics, and Precision Cancer Therapeutics.
Cancer Genomics: My research in this area focuses on the characterization of genetic mutations from cancer genomes to identify driver mutations and the development of experimental therapeutics to target driver genes in ovarian cancer.
Functional Genomics: To translate the genetic information into biological insights and effective anti-cancer therapies, it is important to understand the effect of somatic mutations and develop drugs to exploit somatic mutations. Currently, we are performing functional genetic screens and selections to systematically characterize the effect of somatic mutations in specific cancer genes. The ultimate goal is to develop a catalog of mutations in specific cancer genes and identify drugs that can precisely target these mutations. This work is being funded by the American Cancer Society Research Scholar Grant (125618-RSG-14-067-01-TBE).
Precision Cancer Therapeutics: The primary objective is to develop effective therapies for ovarian cancer. We are focusing on the unfolded protein response (UPR) pathway to induce cytotoxic effects in cancer cells. In particular, we are developing rational combination of novel therapeutics that target UPR pathway to induce immunogenic cell death and to enhance cisplatin sensitivity in ovarian cancer cells. This work is funded by the pending Department of Defense Ovarian Cancer Research Program (W81XWH-17-1-0078).
Service
reviewer of
- Scientific Reports (Journal) 2016 -
- BMC Cancer (Journal) 2015 -
Background
education and training
- Ph.D. in Reproductive Physiology, University of Kansas Medical Center , Physiology 1994 - 2000
- B.S. in Biology, Pittsburg State University , Biology 1991 - 1993
- Mayo Clinic , Pathology and Laboratory Medicine 2000 - 2004
Contact
full name
- Jeremy Chien
mailing address
-
2325 Camino de Salud NE, Cancer Research Facility (Bldg #229), University of New Mexico
Albuquerque, New Mexico 87131
United States of America
Identity
ORCID iD
- http://orcid.org/0000-0003-4744-8374 (pending confirmation)
eRA Commons ID
- CHIEN1